iShares US Pharmaceuticals ETF
102 hedge funds and large institutions have $311M invested in iShares US Pharmaceuticals ETF in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 4 closing their positions.
425% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more capital invested
Capital invested by funds: $259M → $311M (+$52.1M)
19% more funds holding
Funds holding: 86 → 102 (+16)
6.69% more ownership
Funds ownership: 105.34% → 112.03% (+6.7%)
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
Top Buyers
| 1 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
+$15.1M |
| 2 |
BWM
Braver Wealth Management
Needham,
Massachusetts
|
+$11.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.2M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3.46M |
| 5 |
SG Americas Securities
New York
|
+$2.83M |
Top Sellers
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$12.1M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.76M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.3M |
| 5 |
Morgan Stanley
New York
|
-$810K |
IHE Hedge Fund Activity: Q4 2014 in Review
102 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2014, worth a combined $311M — up 20% from $259M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IHE positions and 4 closed out — a net gain of 17 holders — while 31 added to existing stakes and 30 trimmed.
The largest buyer was Brookstone Capital Management, opening a new position worth an estimated $15.1M. The largest seller was Bank of Montreal, cutting an estimated $12.1M.
- 102 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2014, up from 86 in Q3 2014.
- Funds reported $311M of iShares US Pharmaceuticals ETF stock for Q4 2014, up 20% quarter-over-quarter.
- 21 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2014 and 4 closed out, a net change of +17 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2014 was Brookstone Capital Management, an estimated $15.1M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2014 was Bank of Montreal, an estimated $12.1M sold.
Based on aggregated 13F filings for Q4 2014.